ABBV
AbbVie Inc
NYSE: ABBV · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$227.73
+1.32% today
Updated 2026-06-12
Market cap
$380.57B
P/E ratio
105.07
P/S ratio
6.06x
EPS (TTM)
$2.05
Dividend yield
3.17%
52W range
$176 – $239
Volume
6.2M
AbbVie Inc (ABBV) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed ABBV price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$227.73
Today
Analyst consensus
$252.90
+11.05% · 12M
2030 Base
$276.53
+21.43% future
NPV today
$209.56
@ 6% WACC
32 analysts:
19 Buy4 Hold0 Sell
Management guidance
AbbVie raised FY2026 adjusted EPS guidance to $14.28 (from prior $13.90) and net revenue guidance to $68.60B following strong Q1 2026 results ($15B revenue, +12.43% QoQ). Management projects Skyrizi and Rinvoq combined growth exceeding 20% in 2026, with neuroscience franchise accelerating (26% YoY in Q1). No specific 2027-2030 revenue targets disclosed, but guided by immunology transition offsetting Humira biosimilar erosion.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
ABBV · AbbVie Inc · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$168.05
NPV today: $127.35
Base case (2030)
$276.53
NPV today: $209.56
Bull case (2030)
$385.02
NPV today: $291.78
WallStSmart.com
ABBV financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $61.2B | $68.6B | $76.2B | $83.5B | $90.1B | $96.8B |
| Revenue growth | 8.6% | 12.2% | 11.1% | 9.5% | 7.9% | 7.4% |
| Net margin | — | 37.5% | 39.2% | 39.7% | 39.8% | 39.8% |
| EPS | $10.00 | $14.53 | $16.82 | $18.65 | $20.12 | $21.58 |
| Diluted shares | — | 1770M | 1774M | 1777M | 1781M | 1785M |
| Net debt | — | $51.54B | $38.12B | $23.42B | $7.56B | $-9.48B |
| P/S multiple | — | 5.0x | 5.0x | 5.0x | 5.0x | 5.0x |
| Implied price (base) | — | $164.64 | $193.29 | $221.71 | $248.71 | $276.53 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $96.8B | $96.8B | $96.8B |
| P/S multiple | 3.0x | 5.0x | 7.0x |
| Diluted shares | 1785M | 1785M | 1785M |
| Net debt | $-9.48B | $-9.48B | $-9.48B |
| Implied P/E † | 8x | 13x | 18x |
| 2030 Price | $168.05 | $276.53 | $385.02 |
| NPV @ 6% | $127.35 | $209.56 | $291.78 |
† Implied P/E: Multiples remain elevated across all three scenarios because ABBV is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $276.53 base case
ABBV catalysts and risks
Growth catalysts
+ Skyrizi label expansions (Crohn's disease subcutaneous induction, severe alopecia areata via Rinvoq) driving immunology franchise 20%+ growth
+ Neuroscience momentum (Vraylar, Ubrelvy, Qulipta, tavapadon for Parkinson's) sustaining 25%+ YoY growth in segment
+ Allergan aesthetics integration and Botox therapeutic expansion offsetting Humira decline
+ $1.4B North Carolina manufacturing campus supporting scale
+ Pipeline advancement in oncology (mirvetuximab soravtansine in ovarian cancer) and gastrointestinal indications
Key risks
- Humira revenue erosion accelerating beyond guidance as biosimilar penetration increases post-2026
- Competitive pressure from J&J (Icotyde oral psoriasis), Eli Lilly (tirzepatide, GLP-1s) in immunology and weight-loss markets
- Regulatory delays or label setbacks for pipeline candidates (Skyrizi GI expansion, tavapadon, TrenibotE)
- Trump drug pricing policies ("most favored nation" orders, IRA Medicare negotiation) impacting margins and revenue pricing power
- Market share losses in neuroscience if competitors launch comparable therapies at lower cost
Methodology · AbbVie Inc 2030 stock forecast model
AbbVie Inc 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 32 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (1% cumulative for ABBV by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($-9.48B by 2030) |
| 3. Time value | NPV calculated using 6% WACC (CAPM: beta 0.305) |
| 4. Multiple framework | P/S compresses with scale: bear 3.0x / base 5.0x / bull 7.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
ABBV price target FAQ
What is the ABBV price target for 2030?
WallStSmart's AbbVie Inc 2030 base case is $276.53 per share, with a bull case of $385.02 and bear case of $168.05. The NPV of the base case discounted to today at 6% WACC is $209.56.
How is the AbbVie Inc 2030 stock forecast calculated?
The ABBV 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the ABBV price target account for dilution?
AbbVie Inc is projected to grow diluted share count from 1767M to 1785M by 2030 (a 1% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 1%.
What is the analyst consensus on ABBV stock?
32 analysts cover ABBV with an average 12-month price target of $252.90. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.